Affinity Asset Advisors LLC Increases Position in Nurix Therapeutics, Inc. $NRIX

Affinity Asset Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 19.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 967,620 shares of the company’s stock after buying an additional 156,951 shares during the period. Nurix Therapeutics makes up approximately 1.5% of Affinity Asset Advisors LLC’s holdings, making the stock its 22nd largest position. Affinity Asset Advisors LLC’s holdings in Nurix Therapeutics were worth $11,021,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Nurix Therapeutics by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 4,415,122 shares of the company’s stock valued at $52,452,000 after acquiring an additional 69,856 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in shares of Nurix Therapeutics by 2.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 2,428,283 shares of the company’s stock valued at $28,849,000 after purchasing an additional 47,855 shares during the period. Geode Capital Management LLC raised its stake in shares of Nurix Therapeutics by 9.1% during the second quarter. Geode Capital Management LLC now owns 1,881,960 shares of the company’s stock worth $21,437,000 after purchasing an additional 157,592 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Nurix Therapeutics by 84.1% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,391,638 shares of the company’s stock worth $15,851,000 after purchasing an additional 635,668 shares during the period. Finally, Vestal Point Capital LP grew its position in Nurix Therapeutics by 132.1% in the 1st quarter. Vestal Point Capital LP now owns 1,125,552 shares of the company’s stock valued at $13,372,000 after buying an additional 640,552 shares during the last quarter.

Nurix Therapeutics Stock Up 0.4%

Shares of NRIX stock opened at $18.09 on Friday. The stock has a market cap of $1.39 billion, a P/E ratio of -6.09 and a beta of 1.87. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $22.95. The business has a fifty day simple moving average of $12.58 and a 200-day simple moving average of $11.39.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The business had revenue of $7.89 million for the quarter, compared to analyst estimates of $16.06 million. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NRIX. Royal Bank Of Canada restated an “outperform” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, October 22nd. Truist Financial assumed coverage on shares of Nurix Therapeutics in a report on Monday, November 24th. They set a “buy” rating and a $30.00 price target for the company. Mizuho assumed coverage on Nurix Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $24.00 price objective on the stock. Wells Fargo & Company cut their target price on Nurix Therapeutics from $22.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, October 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $26.00 price target on shares of Nurix Therapeutics in a report on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $26.33.

Insider Activity at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,087 shares of the company’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $12.80, for a total value of $52,313.60. Following the sale, the insider owned 76,751 shares of the company’s stock, valued at approximately $982,412.80. This represents a 5.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 6,284 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total value of $78,927.04. Following the sale, the chief financial officer owned 37,592 shares in the company, valued at approximately $472,155.52. This trade represents a 14.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,501 shares of company stock valued at $171,305 over the last 90 days. Insiders own 7.40% of the company’s stock.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.